遗传性视网膜变性的早期与晚期基因治疗干预
遗传性和年龄相关性视网膜变性是当前不可治盲的主要原因,遗传因素在单基因病(如视网膜色素变性)和复杂疾病(如年龄相关性黄斑变性)中均起重要致病作用。基因分型技术和眼后段成像的进展增进了对疾病表现的理解,多数视力丧失源于光感受器功能丧失,其时机和情况决定治疗策略。基因治疗正快速成为临床现实,本文综述现有视网膜基因治疗模式及其基于遗传性视网膜变性患者需求的适用性。
要点
- 遗传性视网膜变性视力丧失多源于光感受器功能丧失,治疗时机决定策略。
- 基因治疗正从实验室走向临床,得益于遗传机制、载体和基因编辑系统进展。
- 本文综述现有视网膜基因治疗模式及其在遗传性视网膜变性患者中的适用性。
核心结论
- 基因治疗正快速成为可用于临床的治疗现实,其模式需基于遗传性视网膜变性患者群体的需求选择。
研究设计与样本
- 本文为综述,概述现有视网膜基因治疗模式及其与遗传性视网膜变性患者需求的相关性。
主要发现
- 遗传因素在单基因病如视网膜色素变性和复杂疾病如年龄相关性黄斑变性中均起重要致病作用。
- 多数视网膜疾病的视力丧失源于光感受器功能丧失,其发生时机和情况决定每位患者的适当治疗方法。
- 基因分型技术和眼后段成像的进展增进了对疾病表现的理解。
- 对疾病遗传学和机制、基因递送载体、基因编辑系统及光感受器功能丧失补偿策略的理解进展推动了基因治疗向临床转化。
临床怎么用
- 临床选择基因治疗策略时需考虑光感受器功能丧失的时机和情况,并基于患者群体需求选择现有基因治疗模式。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Inherited and age-related retinal degeneration is the hallmark of a large group of heterogeneous diseases and is the main cause of untreatable blindness today. Genetic factors play a major pathogenic role in retinal degenerations for both monogenic diseases (such as retinitis pigmentosa) and complex diseases with established genetic risk factors (such as age-related macular degeneration). Progress in genotyping techniques and back of the eye imaging are completing our understanding of these diseases and their manifestations in patient populations suffering from retinal degenerations. It is clear that whatever the genetic cause, the majority of vision loss in retinal diseases results from the loss of photoreceptor function. The timing and circumstances surrounding the loss of photoreceptor function determine the adequate therapeutic approach to use for each patient. Among such approaches, gene therapy is rapidly becoming a therapeutic reality applicable in the clinic. This massive move from laboratory work towards clinical application has been propelled by the advances in our understanding of disease genetics and mechanisms, gene delivery vectors, gene editing systems, and compensatory strategies for loss of photoreceptor function. Here, we provide an overview of existing modalities of retinal gene therapy and their relevance based on the needs of patient populations suffering from inherited retinal degenerations.
引用
- Botto C, Rucli M, Tekinsoy MD, et al. Early and late stage gene therapy interventions for inherited retinal degenerations. Prog Retin Eye Res. 2021. PMID: 34058340. doi:10.1016/j.preteyeres.2021.100975
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。